Form 4: Lexeo Therapeutics CEO Exercises and Sells Shares Under 10b5-1 Plan

Lexeo Therapeutics CEO Richard Nolan Townsend exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Richard Nolan Townsend, CEO of Lexeo Therapeutics, exercised 2,500 stock options at a price of $2.33 per share on December 10, 2024.
• On the same day, Mr. Townsend sold 2,500 shares of common stock at a weighted average price of $8.1965, with individual trades ranging from $7.98 to $8.54.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 19, 2023.
• Following these transactions, Mr. Townsend beneficially owns 120,695 shares of common stock, which includes 43,750 restricted stock units (RSUs).
• Mr. Townsend also holds options for 118,655 shares of common stock.

Sentiment

Score: 5

Explanation: The document reflects routine insider transactions under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine filing related to insider transactions, which are common for executives of publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies to manage their personal finances while avoiding potential insider trading issues.
• The reported transactions are typical for executives who receive stock options and restricted stock units as part of their compensation packages.
• The price range of the share sale is within the expected range for a company of this type.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-arranged trading plan.

Key Dates

Keywords

Lexeo Therapeutics, Richard Nolan Townsend, stock options, share sale, 10b5-1 plan, insider trading, executive compensation, equity